A number of other institutional investors have also added to or reduced their stakes in TEVA.
While looking at the Stock's Performance, Teva Pharmaceutical Industries Limited now shows a Weekly Performance of -3.38%, where Monthly Performance is -19.67%, Quarterly performance is -52.51%, 6 Months performance is -52.74% and yearly performance percentage is -65.66%. Volume totaled around 7.7 million shares, more than three times the daily average. TT International boosted its stake in shares of Teva Pharmaceutical Industries Limited by 2.8% during the 2nd quarter. Share performance for the month is now at -3.36%.
NMIH's price to sales ratio for trailing twelve months is 5.15 and price to book ratio for most recent quarter is 1.58, whereas price to cash per share for the most recent quarter is 38.26.
WARNING: "Sterneck Capital Management LLC Has $4.38 Million Stake in Teva Pharmaceutical Industries Limited (TEVA)" was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. Finally, Elite Wealth Management LLC acquired a new position in Teva Pharmaceutical Industries during the third quarter valued at $166,000.
On Thursday, Teva Pharmaceutical Industries Limited (NYSE:TEVA) reached at $15.15 price level during last trade its distance from 20 days simple moving average is -11.22%, and its distance from 50 days simple moving average is -13.27% while it has a distance of -47.40% from the 200 days simple moving average. The company's Market capitalization is $33.29B with the total Outstanding Shares of 151.36M. The price/earnings to growth ratio (PEG ratio) is a stock's price-to-earnings (P/E) ratio divided by the growth rate of its earnings for a specified time period. Now the stock price is moving -4.20% off from the highest level of twelve months and 29.87% above from twelve months low. According to these analysts, the Low Revenue Estimate for Teva Pharmaceutical Industries Limited is 5.52 Billion and the High Revenue Estimate is 5.76 Billion. The company has market cap of $15.62 billion. After $0.53 actual earnings per share reported by A. O. Smith Corp for the previous quarter, Wall Street now forecasts 0.00% EPS growth. Teva Pharmaceutical Industries had a return on equity of 17.46% and a net margin of 1.50%.
In case of Revenue Estimates, 19 analysts have provided their consensus Average Revenue Estimates for Teva Pharmaceutical Industries Limited as 5.64 Billion. During the same period in the prior year, the business posted $1.25 earnings per share. The company's quarterly revenue was up 12.9% compared to the same quarter a year ago. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has noticeable measure of stock volatility, for this average true range is an exponential moving average (14 trading days) of the True Ranges.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 22nd. They expect $0.63 EPS, up 1.61% or $0.01 from last year's $0.62 per share. The company was maintained on Friday, August 4 by Maxim Group. TT International now owns 179,573 shares of the company's stock worth $5,965,000 after purchasing an additional 4,827 shares during the last quarter. Teva Pharmaceutical Industries's dividend payout ratio is now 1,657.38%.
Several research firms have issued reports on TEVA.
When it comes to the Analysis of a Stock, Price Target plays a vital role. During the last month, the stock has changed 17.30% and performed 42.39% over the last 6 months. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has "Buy" rating given on Monday, July 18 by HSBC. Credit Suisse Group AG reissued a "buy" rating and issued a $39.00 price target on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 17th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company's stock. This company shares are 50.76% off its target price of $22.84 and the current market capitalization stands at $18.08B.